Open AccessFixed dose long-acting bronchodilator combinations in chronic obstructive pulmonary disease: safety, effectiveness and cardiovascular system
Author(s) -
И. В. Лещенко
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-15-18-26
Subject(s) - copd , medicine , bronchodilator , contractility , pulmonary disease , anticholinergic , bronchodilator agents , pulmonary function testing , cardiology , intensive care medicine , anesthesia , asthma
At present time, long-acting bronchodilators are the main class of drugs for basis therapy of chronic obstructive pulmonary disease (COPD). COPD is characterized not only by a decrease in pulmonary function parameters, but also by a decline in cardiac contractility. The article presents the results of studies of four approved fixed long-acting anticholinergic drugs/long-acting beta2-agonists in the Russian Federation, according their effect on the cardiovascular system. The safety of LAMA/ LABA was proved in terms of relation to the cardiovascular system, additionally the positive effect on the pumping function of the heart was shown in patients with COPD, which confirms the value of dual bronchodilators for COPD treatment.